PMID- 12517243
OWN - NLM
STAT- MEDLINE
DCOM- 20040520
LR  - 20190916
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 4
IP  - 1
DP  - 2003 Jan
TI  - Current pharmacotherapeutic options for treating deep vein thrombosis.
PG  - 55-65
AB  - The treatment of deep vein thrombosis (DVT) has been evolving over the past 50 
      years. Initially, unfractionated heparin (UFH) given subcutaneously every 6 h, 
      progressed to constant infusion therapy followed by warfarin, which has become 
      the mainstay of therapy. Over the past 12 years, a new therapy, low molecular 
      weight heparin (LMWH), has proven to be at least as effective or more effective 
      than UFH in the acute treatment of DVT. These drugs are administered 
      subcutaneously, are better absorbed and do not require monitoring. LMWHs have 
      changed the paradigm of caring for patients with DVT. Finally a number of studies 
      with thrombolytic agents have attempted to improve the outcome of DVT by reducing 
      clot burden and preventing the sequelae of thrombotic valvular damage. This paper 
      will review the management of DVT from the acute phase to long-term management.
FAU - Merli, Geno J
AU  - Merli GJ
AD  - Department of Medicine, Jefferson Medical College, Thomas Jefferson University 
      Hospital, PA, USA. Geno.Merli@mail.tju.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Disease Management
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Long-Term Care
MH  - Venous Thrombosis/*drug therapy/physiopathology
RF  - 55
EDAT- 2003/01/09 04:00
MHDA- 2004/05/21 05:00
CRDT- 2003/01/09 04:00
PHST- 2003/01/09 04:00 [pubmed]
PHST- 2004/05/21 05:00 [medline]
PHST- 2003/01/09 04:00 [entrez]
AID - 10.1517/14656566.4.1.55 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2003 Jan;4(1):55-65. doi: 10.1517/14656566.4.1.55.